Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/17/24 12:04 | 4/17/24 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Jones Douglas Edward | MI | O | COO | 3 | P | 320 | 14.23 | 0 | 23 | 95 | 46 | D | ||||||||||||||
4/11/24 11:40 | 4/11/24 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Borel James C | DE | D | 1 | P | 98 | 13.06 | 0 | 8 | 54 | 21 | D | |||||||||||||||
4/10/24 16:18 | 4/10/24 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Naemura David H. | MI | O | CFO | 2 | P | 307 | 13.63 | 0 | 23 | 298 | 30 | D | ||||||||||||||
4/10/24 14:25 | 4/10/24 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | MI | O | CEO | 1 | P | 284 | 12.36 | 0 | 23 | 18 | 152 | D | ||||||||||||||
11/3/23 13:59 | 11/3/23 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Boehm William T | D | 1 | P | 32 | 16.06 | 0 | 2 | 8 | 27 | D | ||||||||||||||||
10/12/23 16:01 | 10/12/23 | NEOG | Health | Diagn | In Vitro & In Vivo Diagnostic | Tobin James P | MI | D | 1 | P | 46 | 15.19 | 0 | 3 | 17 | 20 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |